AXSM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
259.7M
+18.9%
218.4M
+14.2%
191.2M
-2.4%
196.0M
+14.6%
171.0M
Cost of Revenue
17.8M
+31.3%
13.6M
-7.9%
14.7M
+19.4%
12.3M
+3.5%
11.9M
Gross Profit
241.9M
+18.1%
204.8M
+16.1%
176.5M
-3.9%
183.7M
+15.5%
159.1M
Operating Expenses
253.0M
-0.6%
254.5M
+6.1%
239.8M
+13.9%
210.6M
+2.7%
205.2M
R&D
50.6M
+9.5%
46.2M
-12.2%
52.7M
+8.0%
48.8M
+21.5%
40.2M
SG&A
203.1M
-2.4%
208.1M
+12.5%
185.0M
+9.3%
169.3M
+12.7%
150.2M
Operating Income
-11068000
+77.7%
-49646000
+21.6%
-63357000
-135.0%
-26957000
+41.5%
-46109000
EBITDA
-9333000
+80.5%
-47914000
+22.3%
-61669000
-144.4%
-25236000
+43.1%
-44382000
Net Income
-12877000
+74.9%
-51314000
+20.5%
-64542000
-126.0%
-28559000
+39.5%
-47229000
EPS (Basic)
$-0.25
+74.7%
$-0.99
+21.4%
$-1.26
-125.0%
$-0.56
+40.4%
$-0.94
EPS (Diluted)
$-0.25
+74.7%
$-0.99
+21.4%
$-1.26
-125.0%
$-0.56
+40.4%
$-0.94
Shares (Diluted)
52.4M
+1.2%
51.8M
+1.2%
51.2M
+1.1%
50.7M
+1.3%
50.0M
Axsome Therapeutics (AXSM) — Financials